Tandem Diabetes Care Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care or view top-rated stocks.

Wall Street analysts have given Tandem Diabetes Care a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tandem Diabetes Care wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Tandem Diabetes Care saw a increase in short interest during the month of July. As of July 30th, there was short interest totaling 3,900,000 shares, an increase of 15.0% from the July 15th total of 3,390,000 shares. Based on an average trading volume of 552,300 shares, the short-interest ratio is presently 7.1 days. Approximately 6.4% of the shares of the company are sold short.
View Tandem Diabetes Care's Short Interest.

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Tandem Diabetes Care.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted its quarterly earnings results on Wednesday, August, 4th. The medical device company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.14. The medical device company earned $172.14 million during the quarter, compared to the consensus estimate of $143.36 million. Tandem Diabetes Care had a trailing twelve-month return on equity of 3.68% and a net margin of 1.08%. Tandem Diabetes Care's quarterly revenue was up 57.6% on a year-over-year basis. During the same period last year, the business earned ($0.45) EPS.
View Tandem Diabetes Care's earnings history.

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TNDM shares have increased by 84.6% and is now trading at $122.43.
View which stocks have been most impacted by COVID-19.

Tandem Diabetes Care shares reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care issued an update on its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $670 million-$685 million, compared to the consensus revenue estimate of $637.16 million.

8 brokerages have issued 1-year price targets for Tandem Diabetes Care's shares. Their forecasts range from $90.00 to $153.00. On average, they expect Tandem Diabetes Care's stock price to reach $128.63 in the next year. This suggests a possible upside of 5.1% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care or view top-rated stocks among Wall Street analysts.

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

Some companies that are related to Tandem Diabetes Care include Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), NovoCure (NVCR), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), ShockWave Medical (SWAV), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Nevro (NVRO), Merit Medical Systems (MMSI) and Inari Medical (NARI).
View all of TNDM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Tandem Diabetes Care's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.51%), Vanguard Group Inc. (8.89%), Jackson Square Partners LLC (5.75%), BlackRock Inc. (5.59%), Credit Suisse AG (2.67%) and Invesco Ltd. (2.54%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, James Leal, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care.

TNDM stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Price T Rowe Associates Inc. MD, Compagnie Lombard Odier SCmA, Invesco Ltd., Renaissance Technologies LLC, FMR LLC, Morgan Stanley, and Morgan Stanley. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, James Leal, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, and Rebecca B Robertson.
View insider buying and selling activity for Tandem Diabetes Care or view top insider-selling stocks.

TNDM stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Bellevue Group AG, Amundi, State Street Corp, Point72 Asset Management L.P., Man Group plc, Champlain Investment Partners LLC, and Bank of Nova Scotia.
View insider buying and selling activity for Tandem Diabetes Care or or view top insider-buying stocks.

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TNDM stock can currently be purchased for approximately $122.43.

Tandem Diabetes Care has a market capitalization of $7.72 billion and generates $498.83 million in revenue each year. The medical device company earns $-34,380,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

Tandem Diabetes Care employs 1,500 workers across the globe.

Tandem Diabetes Care was founded in 2006.

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Tandem Diabetes Care is headquartered at 11075 ROSELLE STREET, San Diego CA, 92121.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at (858) 366-6900 or via email at [email protected].